Authors

Latest:

Dr. Mitchell on ECOG-ACRIN’s Efforts in Addressing Health Disparities in Cancer Care

Edith P. Mitchell, MD, MACP, FCPP, FRCS, shared the inspiration behind the ECOG-ACRIN Health Equity Committee, and discusses ECOG-ACRIN’s efforts in addressing health disparities in cancer care.

Editorial Staff

Latest:

Top 5 Contagion® News Articles for the Week of August 27, 2017

Stay up-to-date on the latest infectious disease news by checking out this snapshot of our top 5 articles of the week.

Edouard J. Trabulsi, MD

Latest:

Dr. Trabulsi on Clinical Trial Combination Approaches in Prostate Cancer

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses clinical trials that are investigating combination approaches for patients with prostate cancer.

Edouard J. Trabulsi, MD, FACS

Latest:

Dr. Trabulsi Discusses Postoperative Radiation in Prostate Cancer

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses postoperative radiation in patients with prostate cancer.

Eduardo Fernandez, MD

Latest:

Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.

Eduardo Fernandez MD, PhD

Latest:

Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation

Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.

Eduardo Fernandez, MD, PhD, FACRO

Latest:

Dr. Fernandez Discusses Immunotherapy Plus Radiation Therapy for Prostate Cancer

Eduardo Fernandez, MD, PhD, FACRO, Senior Vice President, Medical Affairs / Medical Director for Latin America, Radiation Oncologist, 21st Century Oncology, discusses the potential for immunotherapy and radiation therapy to be used together to treat prostate cancer.

Eduardo G. Moros, PhD

Latest:

Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal Effects

The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.

Eduardo Sotomayor, MD

Latest:

Dr Sotomayor on the Integration of BTK Inhibitors into the CLL Treatment Arsenal

Eduardo Sotomayor, MD, discusses the current arsenal of BTK inhibitors in chronic lymphocytic leukemia.

Eduardo Sotomayor, MD, GW Cancer Center

Edward A. Eikman, MD

Latest:

Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck Cancers

Researchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.

Edward A. Levine, MD

Latest:

Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis

The management of patients with malignant peritoneal surface disease (PSD) commonly known as "carcinomatosis" continues to evolve.

Edward A. Stadtmauer, MD

Latest:

Dr. Stadtmauer on the Evolving Treatment Landscape in Multiple Myeloma

Edward A. Stadtmauer, MD, discusses the evolving treatment landscape in multiple myeloma.

Edward A. Stadtmauer, MD, University of Pennsylvania

Edward B. Garon, MD

Latest:

Dr. Garon on the Role of Trastuzumab Deruxtecan in Lung Cancer

Edward B. Garon, MD, discusses remaining questions with fam-trastuzumab deruxtecan-nxki in the field of lung cancer.

Edward B. Garon, MD, David Geffen School of Medicine at UCLA

Edward B. Garon, MD, MS

Latest:

The Future of Tumor Agnostic Therapies in EGFRm m NSCLC

Experts discuss the expanding treatment landscape for EGFR-mutated non–small cell lung cancer (NSCLC), highlighting emerging strategies beyond tyrosine kinase inhibitors (TKIs)—including novel immunotherapy combinations and antibody-drug conjugates (ADCs)—with particular interest in bispecific antibodies and TROP2-directed ADCs that may offer new options for patients progressing on targeted therapy, despite ongoing challenges in translating immune-based approaches into consistent survival gains.

Edward Bradley, MD

Latest:

Dr. Bradley on OX40 for the Treatment of Cancer

Edward Bradley, MD, from MedImmune (the global biologics research and development arm of AstraZeneca), describes the development of an agonist for the treatment of cancer.

Edward Garon, MD

Latest:

Dr Garon on Considerations for Perioperative Immunotherapy Use in Lung Cancer

Edward B. Garon, MD, MS, discusses key considerations when selecting an optimal perioperative treatment approach for patients with lung cancer.